Doxazosin Sandoz

Doxazosin Sandoz is a generic medicinal product used primarily to treat hypertension and symptoms of benign prostatic hyperplasia. Sandoz, the brand behind the product, is a global leader in generic and biosimilar medicines.

Historically, Sandoz has roots dating back to 1886 in Switzerland. While it was a cornerstone division of Novartis for many years, Sandoz became a fully independent, publicly traded company in late 2023. The manufacturing of Doxazosin occurs in various global facilities authorized by the Sandoz supply chain, often including sites in Europe and Asia to ensure widespread accessibility.

As an independent entity, Sandoz Group AG is headquartered in Switzerland and continues to focus on making high-quality healthcare affordable worldwide. The product is distributed locally through various regional Sandoz subsidiaries depending on the market.